Skip to main content
Equibles
INO logo

INO · Inovio Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio

Track INO — free

Use INO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research INO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.13 -0.03 (-2.17%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We do not currently have sufficient working capital to fund our planned operations for the next twelve months and substantial doubt exists as to our ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Customer concentration — key customers 100% of revenue

Key customers — 100% of revenue (the years ended December 31, 2025 and 2024)

“During the years ended December 31, 2025 and 2024, we derived 100% of our revenue from ApolloBio.”
View the 10-K filed Mar 12, 2026
Market Cap
$122.01M
Shares
103.40M
Volume · Oct 6 1.24M Avg daily vol (3M) 3.76M

Inovio Pharmaceuticals, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Inovio Pharmaceuticals, Inc. (INO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲3038.2% $9.15M −$37.78M '22 Q3 22-11-08 ▼85.1% $124,666 −$54.46M '22 Q4 23-03-01 ▼42.3% $114,943 −$40.65M '23 Q1 23-05-10 ▼71.2% $225,971 −$35.53M '23 Q2 23-08-09 ▼95.8% $388,446 −$33.93M '23 Q3 23-11-09 ▼17.7% $102,650 −$25.00M '23 Q4 24-03-06 ▼55.4% $100,762 −$32.24M '24 Q2 24-08-08 ▼100% $ −$30.47M '24 Q1 24-08-08 ▼100% $ −$25.17M '24 Q3 24-11-14 ▲14% $116,994 −$19.38M '24 Q4 25-03-18 · $65,343 −$19.69M '25 Q1 25-05-13 ▼100% $ −$23.52M '25 Q2 25-08-12 · $ −$45.50M '25 Q3 25-11-10 ▼100% $ $3.76M '25 Q4 26-03-12 ▼100% $ −$19.68M '26 Q1 26-05-13 LATEST · $ −$6.01M '26 Q2 26-08-12
Conference
Investor event
2026-09-11
Inovio Pharmaceuticals, Inc. (INO) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-11
Inovio Pharmaceuticals, Inc. (INO) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-12
Inovio Pharmaceuticals, Inc. (INO) Q2 2026 Earnings Call Transcript
Confident tone INO-3107 clinical and product profile VGX-3100 China partnership Financial runway and capital needs
Revenue
$
Diluted EPS
$-0.07
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-04
Inovio Pharmaceuticals, Inc. (INO) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-13
Inovio Pharmaceuticals, Inc. (INO) Q1 2026 Earnings Call Transcript
Positive tone Accelerated Approval Eligibility / Unmet Need INO3107 Regulatory Progress / BLA Review FDA Regulatory Uncertainty
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.28
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Inovio Pharmaceuticals, Inc. (INO) Q4 2025 Earnings Call Transcript
Positive tone BLA review and accelerated approval eligibility for INO-3107 Differentiation vs. PAPZIMEOS competitor Commercial launch preparation for RRP market
Revenue
$*
▼ 100% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Inovio Pharmaceuticals, Inc. (INO) Q3 2025 Earnings Call Transcript
Confident tone INO-3107 BLA submission and FDA review DMAb platform technology Commercial readiness and launch preparation
Revenue
$
Diluted EPS
$-0.87
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Inovio Pharmaceuticals, Inc. (INO) Q2 2025 Earnings Call Transcript
Confident tone Clinical efficacy and long-term data for 3107 Confirmatory trial and IND update Commercial launch preparation and pricing
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Inovio Pharmaceuticals, Inc. (INO) Q1 2025 Earnings Call Transcript
Confident tone BLA submission progress for INO-3107 Clinical data and durability Earlier-stage pipeline (DMAbs)
Revenue
$65,343
Diluted EPS
$-0.51
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-18
Inovio Pharmaceuticals, Inc. (INO) Q4 2024 Earnings Call Transcript
Positive tone INO-3107 BLA Submission and Regulatory Progress Durability and Efficacy of 3107 CELLECTRA Device Manufacturing Issue Resolution
Revenue
$116,994*
▲ 14% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-14
Inovio Pharmaceuticals, Inc. (INO) Q3 2024 Earnings Call Transcript
Confident tone INO-3107 lead candidate progress Immune response and mechanism of action data Regulatory engagement
Revenue
$
▼ 100% YoY
Diluted EPS
$-0.89
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-08-08
Inovio Pharmaceuticals, Inc. (INO) Q1 2024 Earnings Call Transcript
Positive tone INO-3107 BLA submission for RRP Regulatory engagement (FDA and Europe) Patient burden of RRP disease
Revenue
$
▼ 100% YoY
Diluted EPS
$-1.31
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Inovio Pharmaceuticals, Inc. (INO) Q2 2024 Earnings Call Transcript
Positive tone INO-3107 BLA submission and manufacturing issue FDA pre-BLA meeting and regulatory progress Redosing and confirmatory trial strategy
Revenue
$100,762
▼ 55.4% YoY
Diluted EPS
$-1.19
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-06
Inovio Pharmaceuticals, Inc. (INO) Q4 2023 Earnings Call Transcript
Confident tone Recurrent Respiratory Papillomatosis (RRP) disease burden Immuno-oncology pipeline (3112, 5401) INO-3107 BLA submission and approval pathway
Revenue
$102,650*
▼ 17.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Inovio Pharmaceuticals, Inc. (INO) Q3 2023 Earnings Call Transcript
Revenue
$388,446
▼ 95.8% YoY
Diluted EPS
$-1.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Inovio Pharmaceuticals, Inc. (INO) Q2 2023 Earnings Call Transcript
Revenue
$225,971
▼ 71.2% YoY
Diluted EPS
$-1.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Inovio Pharmaceuticals, Inc. (INO) Q1 2023 Earnings Call Transcript
Revenue
$114,943
▼ 42.3% YoY
Diluted EPS
$-1.89
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
Inovio Pharmaceuticals, Inc. (INO) Q4 2022 Earnings Call Transcript
Revenue
$124,666*
▼ 85.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Inovio Pharmaceuticals, Inc. (INO) Q3 2022 Earnings Call Transcript
Revenue
$9.15M
▲ 3038.2% YoY
Diluted EPS
$-1.80
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Inovio Pharmaceuticals, Inc. (INO) Q2 2022 Earnings Call Transcript
Revenue
$784,395
▲ 187.5% YoY
Diluted EPS
$-5.52
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Inovio Pharmaceuticals, Inc. (INO) Q1 2022 Earnings Call Transcript
Revenue
$199,074
▼ 46.4% YoY
Diluted EPS
$-4.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2021-12-31
Inovio Pharmaceuticals, Inc. (INO) Q4 2021 Earnings Call Transcript
Revenue
$839,116*
▼ 85% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Inovio Pharmaceuticals, Inc. (INO) Q3 2021 Earnings Call Transcript
Revenue
$291,698
▲ 23.5% YoY
Diluted EPS
$-3.48
▼ 363.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Inovio Pharmaceuticals, Inc. (INO) Q2 2021 Earnings Call Transcript
Revenue
$272,824
▲ 2.1% YoY
Diluted EPS
$-4.68
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Inovio Pharmaceuticals, Inc. (INO) Q1 2021 Earnings Call Transcript
Revenue
$371,120
▼ 72% YoY
Diluted EPS
$-3.24
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Inovio Pharmaceuticals, Inc. (INO) Q4 2020 Earnings Call Transcript
Revenue
$5.58M
▲ 1896.7% YoY
Diluted EPS
$-1.68
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Inovio Pharmaceuticals, Inc. (INO) Q3 2020 Earnings Call Transcript
Revenue
$236,178
▼ 72.8% YoY
Diluted EPS
$1.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-10
Inovio Pharmaceuticals, Inc. (INO) Q2 2020 Earnings Call Transcript
Revenue
$267,187
▲ 96.9% YoY
Diluted EPS
$-9.96
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-11
Inovio Pharmaceuticals, Inc. (INO) Q1 2020 Earnings Call Transcript
Revenue
$1.33M
▼ 53.1% YoY
Diluted EPS
$-3.12
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Inovio Pharmaceuticals, Inc. (INO) Q4 2019 Earnings Call
Revenue
$279,488
▼ 88.8% YoY
Diluted EPS
$-4.56
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–30 of 30 webcasts
Key facts CIK 1055726 CUSIP 45773H409 13F (30d) 1 filings 1 filers Visit website Investor relations